Mercury Pharmaceuticals

13

May 2026

Qureight to support Mediar Therapeutics' Phase 2 trial of MTX-474 in diffuse cutaneous Systemic Sclerosis

Qureight, an end-to-end imaging CRO that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, and Mediar Therapeutics (Mediar), a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced Qureight's AI-powered 3D quantitative imaging analytics platform and services will be used to support Mediar's Phase 2 EncompaSSc clinical trial.

READ MORE

13

May 2026

Base editing approach repairs deadly Dravet syndrome mutation in mice

Gene editing can repair a DNA error in mice that causes Dravet syndrome, a rare, incurable, and potentially deadly form of childhood epilepsy. After the edit, the mice have far fewer seizures and live much longer.

READ MORE

13

May 2026

Wearable wireless polygraph tracks hidden stress signals

Northwestern University engineers have developed a small, wireless polygraph system you can wear.

READ MORE

13

May 2026

Battery-free wearable sensor continuously monitors health through sweat

University of California, Irvine researchers have invented a wearable, wireless, battery-free, bioelectronic sensor to monitor users' health by analyzing molecular biomarkers in human sweat.

READ MORE

13

May 2026

Experts urge WHO to strengthen airborne virus precautionary measures

With three people dead and 11 cases from the recent hantavirus outbreak on a cruise ship, UMD's internationally renowned expert on airborne viruses, Dr. Don Milton, joins public health colleagues in an opinion piece in the British Medical Journal (BMJ) calling on the World Health Organization (WHO) to shift its default response to emerging respiratory viruses.

READ MORE

13

May 2026

Gene panel predicts chemotherapy response in triple-negative breast cancer

Researchers at The University of Texas MD Anderson Cancer Center have characterized cancer cell-specific features in the tumor microenvironment (TME) of early-stage triple-negative breast cancer (TNBC) tissues, identifying specific macrophage subtypes associated with chemotherapy response.

READ MORE

13

May 2026

Next-generation cancer therapy shows early promise as treatment candidate for glioblastoma

A next-generation cancer therapy being developed at McMaster University has shown early promise as a treatment candidate for glioblastoma, the most aggressive and most common type of primary brain cancer in adults.

READ MORE

13

May 2026

Air pollution linked to rising kidney disease hospitalization risks

A study supported by FAPESP and published in the journal Scientific Reports showed a strong correlation between the concentration of particulate matter in the air of São Paulo, Brazil – primarily emitted by vehicle fuel combustion – and kidney disease.

READ MORE

13

May 2026

Immune cell discovery reveals new pathway for hepatitis B treatment

Fifteen years ago, doctors in Europe noticed a remarkable thing happening in people with chronic hepatitis B infections. When patients went off their medications, the virus started to come back - and then some of the patients were cured.

READ MORE

13

May 2026

Obesity drugs and surgery linked to greater fat-free mass loss

A new systematic review and meta-analysis of studies presented at this year's European Congress on Obesity in Istanbul, Turkey (12-15 May) shows that diet and exercise interventions result in a lower proportion of fat-free mass loss compared with obesity surgery or obesity drugs among people undergoing a weight loss of 10% or more.

READ MORE